Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 1.4% – Here’s What Happened

Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded down 1.4% during mid-day trading on Thursday . The stock traded as low as GBX 734 and last traded at GBX 750. 9,378 shares were traded during trading, a decline of 65% from the average daily volume of 26,501 shares. The stock had previously closed at GBX 761.

Hemogenyx Pharmaceuticals Trading Down 1.4%

The company has a market cap of £51 million, a P/E ratio of -4.40 and a beta of 1.50. The business has a fifty day simple moving average of GBX 732.91 and a 200 day simple moving average of GBX 810.24. The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.